Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 16, 2019

SELL
$30.43 - $56.65 $5,294 - $9,857
-174 Closed
0 $0
Q2 2018

Jul 17, 2018

BUY
$46.25 - $104.45 $3,931 - $8,878
85 Added 95.51%
174 $8,000
Q1 2018

Apr 12, 2018

BUY
$57.4 - $108.44 $5,108 - $9,651
89 New
89 $9,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Legacy Financial Advisors, Inc. Portfolio

Follow Legacy Financial Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legacy Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Legacy Financial Advisors, Inc. with notifications on news.